Join structural heart experts as they share their experiences with redo TAV in this insightful 60-minute webinar. Gain valuable knowledge on case planning and case presentations featuring Evolut™ in Evolut TAV and Evolut in SAPIEN™* TAV.
Medtronic Cardiac and Vascular
Medical Device
Minneapolis , MN 239,058 followers
Engineering the Extraordinary
About us
A global healthcare technology leader — boldly attacking the most challenging health problems facing humanity with innovations that transform lives.
- Website
-
http://medtronic.com
External link for Medtronic Cardiac and Vascular
- Industry
- Medical Device
- Company size
- 10,001+ employees
- Headquarters
- Minneapolis , MN
- Founded
- 1949
Updates
-
Don't miss it! Join a panel of experts at #TCT2025 for the featured academic session, Under Pressure: RDN Masters Talk Symplicity™. In this highly interactive session, the panel will discuss Symplicity rf RDN in the real world and will answer your questions. This lunch symposium will be held in the Innovation Theater, Hall E, Exhibition Level, Moscone North. Add it to your calendar today. https://lnkd.in/eS3mdPER Product usage represented may not be approved or cleared in all markets.
-
-
Upcoming Webinar: New DCB indications for everyday practice On Tuesday, October 14, 2025 at 11:00 AM EST, PCR is hosting a webinar focused on the evolving role of drug-coated balloons (DCB) in complex cases. Key topics include: ✔️ Newest indications for DCB use: STEMI, TO/CTO, and bifurcations ✔️ Rationale and potential advantages of avoiding stenting or re-stenting ✔️ Long-term clinical and angiographic results in complex lesions 📍 Register here: https://lnkd.in/eQnsWzVJ Don’t miss this valuable opportunity to hear expert perspectives and explore how these insights can shape everyday practice. †, ‡ † Prevail DCB expanded indications are approved in EU and UK ‡ Only use based on the IFU indications. Refer to respective product IFUs for details
-
You're invited! Prior Authorization, Appeals, and Patient Access Support (PAS). This webinar will give a general overview of the process for requesting prior authorization and appeals from a payer, as well as highlight the PAS team, which can educate and assist with submission of prior authorizations and appeals for the Symplicity™ blood pressure procedure. Join us on October 15, 11:00–11:30 a.m. CT https://lnkd.in/e756WJ9N Product usage represented may not be approved for use in all markets.
-
Thank you to everyone who joined us at EBC 2025 in Amsterdam! Our symposium, “Evolving bifurcation treatment practices,”* brought together global experts to share the latest data and techniques shaping the future of coronary bifurcation care. Special thanks to our chair G. Stankovic, panelists J. Lassen, B. Koo, P. O’Kane, and presenters K. Mashayekhi, F. Burzotta, Y. Sandoval for their invaluable insights. Couldn’t attend? The full symposium recording will be available soon—stay tuned for details. Together, we’re driving meaningful advances in bifurcation treatment for patients worldwide. #EBC2025 #Bifurcation #CoronaryIntervention #DCB #Physiology *Prevail DCB is only approved for the treatment of bifurcation lesions in EU/UK.
-
-
Join our webinar: Prior Authorization, Appeals, and Patient Access Support (PAS). This webinar will give a general overview of the process for requesting prior authorization and appeals from a payer, as well as highlight the PAS team, which can educate and assist with submission of prior authorizations and appeals for the Symplicity™ blood pressure procedure. Join us! October 15, 11:00–11:30 a.m. CT https://lnkd.in/e756WJ9N Product usage represented may not be approved for use in all markets.
-
🚀 Episode 1 of the PFA Conversations: Bite-Sized Insights series is out now! Prof. Reza Wakili and Dr. Gabriel Ballesteros Derbenti dive into signal clarity, lesion definition, and practical reflections for EP labs in just over 20 minutes. Watch now and discover how PulseSelect™ PFA is shaping ablation strategies 👉 https://bit.ly/4mMzO9o #PulseSelect #PFA #epeeps Product usage represented may not be approved or cleared in all markets
💡NEW #PFA Conversations: Bite-Sized Insights series available now! 🥼Beginning with a discussion between Prof Reza Wakili and Dr Gabriel Ballesteros Derbenti on Redefining Borders in PFA Lesion Creation in the pulmonary veins and beyond. 📺 Access Episode 1 now and bring new insights into your own practice 🔗Link in comments. In just over 20 minutes, they explore: ✅ Signal clarity and lesion definition ✅ The potential for isthmus-free lines ✅ Practical reflections for EP labs This series is supported by Medtronic. #AFib #CardioEd #EPeeps #MedEd
-
After our pilot, Affera in Action returns with Episode 2! This time, Prof. Andreas Metzner presents a patient with Ebstein’s anomaly and recurrent atrial tachycardia. ✨ High-density right atrial mapping revealed an extensive lateral scar and a critical isthmus with slow conduction sustaining the tachycardia ⚡ Targeted RF ablation at the center of the isthmus successfully terminated the arrhythmia on the spot ✅ Ablation line connected to adjacent scar ensured complete conduction block and non-inducibility despite aggressive stimulation Sphere-9™ magic: mapping + ablation without exchange, shorter procedures, lasting results. Stay tuned for more Affera in action! https://bit.ly/3V0VjrJ #afferamagic #pfa #epeeps #affera Product usage represented may not be approved or cleared in all markets.
-
Join structural heart experts as they share their experiences with redo TAV in this insightful 60-minute webinar. Gain valuable knowledge on case planning and case presentations featuring Evolut™ in Evolut TAV and Evolut in SAPIEN™* TAV.
Exploring Redo TAV: Indications, planning, and real-world experiences
www.linkedin.com
-
Join us at EBC 2025! As leaders in coronary innovation, we continue to advance treatment options for one of the most complex challenges in interventional cardiology: bifurcation disease. Don’t miss our sponsored symposium: October 4, 2025 15:25 - 15:55 Leonardo Royal Hotel Amsterdam, NL Session: Evolving bifurcation treatment practices Chair: G. Stankovic Panel: J. Lassen, B. Koo, P. O’Kane Presenters: 🔹 Prevail DCB clinical data + case illustration* (SCAAR + EBC DCB) – K. Mashayekhi 🔹 Tackling ostial LCx stenosis – F. Burzotta 🔹 CathWorks FFRangio for physiology-guided side branch intervention – Y. Sandoval Join us as we bring evidence, innovation, and expert perspectives together to shape the future of bifurcation care. Watch the live stream of the event on the EBC YouTube channel. #EBC2025 #CoronaryIntervention #Bifurcation #DCB #PrevailDCB *Prevail DCB is only approved for the treatment of bifurcation lesions in EU/UK.
-